AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02915237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concord grape juice
Description: Daily dietary supplementation with a commercially available Concord grape juice.
Study NCT02915237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
Study NCT03166124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03166124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT00915837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
Study NCT00915837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
Study NCT01367717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
Study NCT01367717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Ethyl Ester
Description: Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
Study NCT00982501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS® 1442 900 mg/d
Study NCT00982501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS® 1442 1800 mg/d
Study NCT00982501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking training 2 x 30 min/week
Study NCT00982501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking training 4x45 min/week
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m² IV on Day 1 during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m² IV on Day 1 during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² IV on Day 1 during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
Study NCT03777657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
Study NCT01839903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDIS
Description: Changes made to EDIS system to improve tracking and treatment of smoking in the ED
Study NCT01839903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Care as usual in the ED will be tracked
Study NCT04537065 — intervention group
Intervention type: OTHER
Intervention: cycloplegic refraction
Description: Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).
Study NCT00822055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye
Study NCT00822055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye
Study NCT00822055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Description: 1 drop BID in each eye
Study NCT00822055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Description: 1 drop BID in each eye
Study NCT02459899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day
Study NCT02459899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day
Study NCT02459899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin,once daily, before the first meal of the day
Study NCT03394027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
Study NCT03310996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
Study NCT03310996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
Study NCT01677104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
Study NCT01677104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-1
Description: GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
Study NCT01677104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01677104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03261596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
Study NCT01792830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.
Study NCT03076047 — intervention group
Intervention type: DEVICE
Intervention: end-tidal CO2 (ETCO2) monitoring
Description: monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
Study NCT02657668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Focused Therapy
Description: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
Study NCT02848690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
Study NCT02848690 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care Intervention Group
Description: Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
Study NCT03764202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Detection of sufentanil concentration
Description: * Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point
Study NCT01792830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose.
Study NCT01792830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glulisine
Description: Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
Study NCT04842669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
Study NCT04842669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: (Topical ibuprofen gel) for muscle soreness will be provided
Study NCT03080038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Sparing Resuscitation Strategy
Description: Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed.
Study NCT02888002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide to better alcohol habits
Description: A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
Study NCT02250716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
Study NCT00820079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration
Study NCT00820079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: oral administration
Study NCT00518726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
Description: seasonal influenza vaccine 15ug
Study NCT00947986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1% Johnson's Baby Shampoo
Description: nasal irrigation 2x a day for 4 weeks
Study NCT01624168 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Anxiety Management Education
Description: written materials on management of anxiety for self-study
Study NCT01624168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 week tai chi intervention
Description: 10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
Study NCT01624168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced tai chi instruction
Description: 10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
Study NCT03302741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BTX)
Description: Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
Study NCT03302741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum neurotoxin (BTX)
Description: Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
Study NCT03302741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
Study NCT03302741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
Study NCT03302741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard BTX injection (ultrasound guided)
Description: For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
Study NCT03302741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-dimensional innervation zone (3DIZ) guided injection
Description: Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
Study NCT00748410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933
Description: 7 days repeat dose
Study NCT02620618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Infliximab
Description: ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
Study NCT02964780 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass surgery
Study NCT02964780 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conservative weight loss program
Study NCT06359054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: 18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position).
Study NCT06359054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga DOTATATE PET/CT
Description: 68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression.
Study NCT00305695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00305695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Given IV
Study NCT02496806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract
Description: Treatment capsule containing seaweed extract (treatment)
Study NCT03433950 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Observational
Study NCT03056079 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal aflibercept
Description: Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
Study NCT03123757 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 Minute Walk Test
Description: The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.